METHOD FOR PREDICTION OF CLINICAL COURSE OF CEREBRAL WOUND DYSTROPHY Russian patent published in 2011 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: for the first hour following admission of a patient with a severe craniocerebral injury (CCI) to hospital, human recombinant erythropoietin (Epocrin) 10000 IU is introduced intravenously. Prior to the introduction of erythropoietin and 24 hours thereon, the blood serum cytokine concentration is evaluated: IL-6, IL-10; red blood cells are analysed for the concentration of malonic dialdehyde (MDA) and superoxide dismutase (SOD). Thereafter, for each of the derived values, its percentage change after the introduction of erythropoietin is determined by calculating the relation of a difference of each of the derived values prior to the introduction of erythropoietin to a related value prior to the introduction of erythropoietin. If the IL-6 concentration is increased by 35 % and more, the IL-10 concentration by 20 % and lower, the red blood cell MDA concentration - by 30 % and more, the SOD concentration by 45 % and less, an unfavourable course of cerebral wound dystrophy is predicted.

EFFECT: use of the method enables high-precise prediction of the cerebral wound dystrophy outcome within the least invasive research, and selection or correction of the conducted intensive care.

2 ex